'Drotrecogin alfa' presentation slideshows

Septic Shock in 2004

Septic Shock in 2004. Emergency Department Strategies for Reducing Mortality Moritz Haager PGY-3 May 13, 2004. Objectives. Brief review of basic pathophysiology Overview of recent advances in treatment with focus on those most relevant to ED care Initial resuscitation

1.51k views • 109 slides

2003-2004 Review of Anticoagulants, Thrombolytics and Anti-platelet Drugs

2003-2004 Review of Anticoagulants, Thrombolytics and Anti-platelet Drugs. 1 April 2014 7:17 AM. Abciximab. Antiplatelet Anti-GPIIb/IIIa receptor antibody. Adalimumab. TNF inhibitor Anti-TNF antibody Used in rheumatoid arthritis. Allopurinol. Antigout Antineoplastic (supporting agent)

1.18k views • 100 slides

THE ETHICS AND SCIENCE OF PLACEBO-CONTROLLED TRIALS

THE ETHICS AND SCIENCE OF PLACEBO-CONTROLLED TRIALS. Susan S. Ellenberg, Ph.D. Director, Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA National Institutes of Health Ethical/Regulatory Aspects of Human Subject Research October 27, 2004. BACKGROUND.

1.08k views • 45 slides

Traitements non Antibiotiques du Choc Septique

678 views • 43 slides

Study F1K-MC-EVAD: Relative Risk under Original and Amended Protocols

Study F1K-MC-EVAD: Relative Risk under Original and Amended Protocols. Relative Risk. Patient Population. Original Protocol. Amended Protocol. Interaction P-Value. Entire Population. 0.94. 0.71. 0.08. Sites Enrolling under Both Protocols. 0.87. 0.77. 0.50. 6586.01. Relative Risk.

346 views • 26 slides

Spotlight Case July 2004

Spotlight Case July 2004. Preventing Inappropriate Use of Novel Therapeutic Agents. Source and Credits. This presentation is based on the July 2004 AHRQ WebM&M Spotlight Case in Critical Care Medicine See the full article at http://webmm.ahrq.gov CME credit is available through the Web site

337 views • 21 slides